ValueQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSelling/general/admin expenses12.59 M13.91 M11.9 M14.52 M11.38 M51.7 MResearch & development43.42 M58.57 M55.5 M47.75 M59.21 M221.04 M영업 이익-45.24 M-48.84 M-62.23 M-62.02 M-70.34 M-243.43 MNon-Operating Income, Total3.93 M3.64 M2.89 M2.29 M2.92 M11.75 MInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses-14 K000-33 K-33 KUnusual income/expense3.94 M3.64 M2.89 M2.29 M2.96 M11.78 MPretax income-41.31 M-45.2 M-59.33 M-59.73 M-67.42 M-231.68 MEquity in earnings——————Taxes90 K093 K0186 K279 KNon-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations-41.4 M-45.2 M-59.43 M-59.73 M-67.61 M-231.96 MDiscontinued operations——————Net income-41.4 M-45.2 M-59.43 M-59.73 M-67.61 M-231.96 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-41.4 M-45.2 M-59.43 M-59.73 M-67.61 M-231.96 MBasic earnings per share (Basic EPS)-0.65-0.65-0.85-0.85-0.82-3.17Diluted earnings per share (Diluted EPS)-0.65-0.65-0.85-0.85-0.82-3.17Average basic shares outstanding56.3 K69.77 M69.93 K70.17 K73.25 K69.98 MDiluted shares outstanding56.3 K69.77 M69.93 K70.17 K73.25 K69.98 MEBITDA-44.77 M-48.34 M-61.69 M-61.45 M-69.86 M-241.33 MEBIT-45.24 M-48.84 M-62.23 M-62.02 M-70.34 M-243.43 MCost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)467 K497 K538 K576 K489 K2.1 M
EyePoint Inc
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner.
In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.